Oncology Journal Publications

This page includes links to Lilly sponsored trials and observational research that have been published in peer reviewed journals within the last 5 years. Each section is sorted by product and may be expanded for more information. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please call 1-800-LILLYRX (1-800-545-5979).

For all other requests, please visit our Contact Lilly services.

Alimta^® (pemetrexed for injection)

Full Prescribing Information

No Publication Journals

Cyramza^® (ramucirumab)

Full Prescribing Information

The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy

Published Date: December 20, 2019

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Published Date: January 20, 2020

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Published Date: January 31, 2020

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

Published Date: April 21, 2020

Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies

Published Date: May 15, 2020

Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

Published Date: December 19, 2019

Published Date: December 20, 2019

No Publication Journals

Risk Thresholds for Patients to Switch Between Daily Tablets and Biweekly Infusions in Second-Line Treatment for Advanced Hepatocellular Carcinoma: a Patient Preference Study

Published Date: January 19, 2023

Real-world Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States

Published Date: February 23, 2023

Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer

Published Date: May 17, 2023

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

Published Date: May 25, 2023

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.

Published Date: February 23, 2022

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Published Date: December 12, 2022

Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States

Published Date: February 2, 2021

Treatment Patterns for Patients with Advanced/Metastatic Cancers by Site-of-Care

Published Date: April 12, 2021

Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration.

Published Date: April 12, 2021

Real-World Characteristics and Outcomes of Advanced NSCLC Patients With EGFR Exon 19 Deletions or Exon 21 Mutations

Published Date: April 19, 2021

Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ NSCLC

Published Date: October 12, 2021

Reliability of conclusions from early analyses of real-world data for newly approved drugs in advanced gastric cancer in the United States

Published Date: April 30, 2020

Erbitux^® (cetuximab)

Full Prescribing Information

No Publication Journals

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies

Published Date: November 26, 2019

No Publication Journals

Jaypirca^® (pirtobrutinib)

Full Prescribing Information

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

Published Date: March 4, 2022

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

Published Date: March 4, 2022

No Publication Journals

Outcomes Among Patients with Mantle Cell Lymphoma post-covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study

Published Date: December 28, 2022

Portrazza^® (necitumumab)

Full Prescribing Information

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer

Published Date: April 1, 2020

No Publication Journals

Retevmo^® (selpercatinib)

Full Prescribing Information

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Published Date: January 24, 2020

Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer

Published Date: February 19, 2020

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations

Published Date: April 14, 2020

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma

Published Date: April 15, 2020

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Published Date: January 24, 2020

Hypercalcemia as a Rebound Phenomenon of LOXO-292 Efficacy in Medullary Thyroid Cancer

Published Date: February 19, 2020

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations

Published Date: April 14, 2020

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma

Published Date: April 15, 2020

No Publication Journals

Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.

Published Date: March 20, 2023

Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer

Published Date: February 12, 2022

Diagnostic Value and Cost-Effectiveness of Next Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer in the United States.

Published Date: July 28, 2022

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021

Published Date: August 15, 2022

Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study.

Published Date: December 8, 2022

Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.

Published Date: February 9, 2021

Verzenio^® (abemaciclib)

Full Prescribing Information

No Publication Journals

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Published Date: April 27, 2020

No Publication Journals

Characteristics and Outcomes in US Male Patients (Pts) with Metastatic Breast Cancer (MBC) Receiving Abemaciclib (Abema) in Routine Clinical Practice

Published Date: April 2, 2023

Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2- MBC in the real world

Published Date: June 14, 2023

Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.

Published Date: March 1, 2022

Adjuvant Abemaciclib Combined With Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study

Published Date: March 22, 2022

A real-world retrospective study of the use of Ki-67 testing and treatment patterns in HR+, HER2- early breast cancer patients in the United States.

Published Date: May 6, 2022

Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.

Published Date: May 10, 2022

A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

Published Date: May 25, 2022

Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+/HER2- metastatic breast cancer treated with abemaciclib

Published Date: September 22, 2022

Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database

Published Date: November 21, 2022

Development of a Prognostic Factor Index among Women with HR+/HER2- Metastatic Breast Cancer in a Community Oncology Setting

Published Date: March 4, 2021

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.

Published Date: May 10, 2021

Predicting Optimal Treatment Regimens for patients with HR+/HER2- Breast Cancer Using Machine Learning Based on Electronic Health Records

Published Date: June 8, 2021

Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2− advanced breast cancer patients with poor prognostic factors: data from an international study

Published Date: August 7, 2021

Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review

Published Date: August 20, 2021

Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.

Published Date: November 3, 2021

KRAS mutation as a prognostic factor and effect modifier in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis

Published Date: July 25, 2020

Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States

Published Date: August 5, 2020

Oncology Journal Publications

Alimta® (pemetrexed for injection)

Expand accordion Phase I (No Publications Available)

Expand accordion Phase II

Expand accordion Phase III

Expand accordion Phase IV (No Publications Available)

Cyramza® (ramucirumab)

Expand accordion Phase I

Expand accordion Phase II

Expand accordion Phase III

Expand accordion Phase IV (No Publications Available)

Expand accordion Real World Evidence

Erbitux® (cetuximab)

Expand accordion Phase I (No Publications Available)

Expand accordion Phase II

Expand accordion Phase III (No Publications Available)

Expand accordion Phase IV (No Publications Available)

Jaypirca® (pirtobrutinib)

Expand accordion Phase I

Expand accordion Phase II

Expand accordion Phase III (No Publications Available)

Expand accordion Phase IV (No Publications Available)

Expand accordion Real World Evidence

Portrazza® (necitumumab)

Expand accordion Phase I

Expand accordion Phase II

Expand accordion Phase III (No Publications Available)

Expand accordion Phase IV (No Publications Available)

Retevmo® (selpercatinib)

Expand accordion Phase I

Expand accordion Phase II

Expand accordion Phase III (No Publications Available)

Expand accordion Phase IV (No Publications Available)

Expand accordion Real World Evidence

Verzenio® (abemaciclib)

Expand accordion Phase I (No Publications Available)

Expand accordion Phase II

Expand accordion Phase III

Expand accordion Phase IV (No Publications Available)

Expand accordion Real World Evidence

Can't find what you're looking for? Contact us for answers to your medical questions.

Alimta^® (pemetrexed for injection)

Cyramza^® (ramucirumab)

Erbitux^® (cetuximab)

Jaypirca^® (pirtobrutinib)

Portrazza^® (necitumumab)

Retevmo^® (selpercatinib)

Verzenio^® (abemaciclib)